ARTICLE | Clinical News

Tokai ending galeterone study

July 26, 2016 7:00 AM UTC

Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) fell $4.10 (79%) to $1.10 on Tuesday after it said it would stop the Phase III ARMOR3-SV study of galeterone ( TOK-001) to treat metastatic castration-resistant prostate cancer (CRPC). Tokai said an independent DMC determined the study is unlikely to meet its primary endpoint of improving radiographic progression-free survival (rPFS) vs. Xtandi enzalutamide.

The study enrolled treatment-naive patients whose tumors express androgen receptor splice variant 7 (AR- V7). Tokai plans to present ARMOR3-SV data in a scientific forum. ...